ArticleSurgical endoscopy2026
Stepwise organ-preserving management of incidental pT1 rectal adenocarcinoma: outcomes after completion transanal endoscopic microsurgery (TEM).
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAccurate in vivo assessment of rectal lesion invasion remains challenging despite advances in high-definition endoscopy and AI-assisted diagnostics. Some lesions resected endoscopically for presumed superficial pathology are ultimately found to contain submucosal invasive adenocarcinoma (pT1), prompting reconsideration of treatment. While total mesorectal excision (TME) remains the standard for radical oncologic removal, its morbidity has increased interest in organ-preserving approaches such as transanal endoscopic microsurgery (TEM).
methodsWe conducted a retrospective, single-centre study including all consecutive patients who underwent TEM after endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) of rectal lesions unexpectedly diagnosed as pT1 adenocarcinoma. Patients treated between 1995 and 2024 with at least 12 months of follow-up were included. Primary endpoints were overall survival (OS) and disease-free survival (DFS); secondary endpoints included residual disease in the TEM specimen and patterns of recurrence.
resultsSixty-six patients were included. TEM identified residual dysplasia in 25 patients (37.9%) but no cases of residual invasive carcinoma. Surgical margins were clear in all cases. Only one patient (1.5%) required salvage TME due to adverse histological features. At a median follow-up of 15 months, OS was 100% and DFS 97%, with two patients (3%) experiencing local recurrence successfully managed with salvage surgery. No distant metastases were observed. No stoma formation or major complications occurred.
conclusionsIn patients with incidental pT1 rectal adenocarcinoma following EMR or ESD, completion TEM provides excellent short-term oncological outcomes with minimal morbidity. This two-step, organ-preserving approach appears oncologically adequate in well-selected low-risk patients and offers a viable alternative to radical surgery, especially when maintaining function is a priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.